Cough Reflex Sensitivity and Bronchial Hyper-responsiveness
16 de febrero de 2017 actualizado por: Kenneth R. DeVault, M.D., Mayo Clinic
Pilot Studies Evaluating Cough Reflex Sensitivity and Bronchial Hyper-responsiveness: The Road to Cough and Wheeze in Patients With Gastroesophageal Reflux.
The aim of this study is to provide pilot data on the possible gastrointestinal predictors of respiratory hyper-responsiveness and how these relate to the clinical sub-types of gastroesophageal reflux disease (GERD) and visceral acid hypersensitivity.
Descripción general del estudio
Estado
Terminado
Intervención / Tratamiento
Descripción detallada
This study recruited participants into three groups: reflux patients with non-erosive disease (NERD) with abnormal levels of acid reflux, NERD patients with normal levels of reflux and healthy volunteers.
Participants were assessed for cough reflex sensitivity (CRS) to citric acid and bronchial-hyperresponsiveness (BHR) to methacholine challenge, both before (baseline) and after esophageal acid infusion (HCl, 0.15M) or normal saline control (8ml/min).
The order of CRS and BHR was randomized, as was the order of the acid/saline infusions.
Tipo de estudio
De observación
Inscripción (Actual)
24
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Florida
-
Jacksonville, Florida, Estados Unidos, 32224
- Mayo Clinic Florida
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años a 60 años (Adulto)
Acepta Voluntarios Saludables
Sí
Géneros elegibles para el estudio
Todos
Método de muestreo
Muestra de probabilidad
Población de estudio
This study will recruit participants into three groups ages 18-60 years: 12 reflux patients with non-erosive disease (NERD) with abnormal levels of acid reflux, 12 NERD patients with normal levels of reflux and 12 healthy volunteers.
Descripción
Inclusion Criteria:
- symptomatic reflux (i.e., one symptom at least one day a week, with at least 'moderate' severity)
- no evidence of esophagitis
- non-smokers
Exclusion Criteria:
- previous gastrointestinal surgery (excluding minor surgeries, such as cholecystectomy, appendectomy
- active peptic ulcer disease
- Zollinger Ellison Syndrome
- Barrett's esophagus
- eosinophilic esophagitis
- cardiac disease
- diabetes or neurological deficit
- use of tricyclics
- selective serotonin reuptake inhibitors
- narcotics or benzodiazepines
- current use of medications that may affect symptoms of perception,lower esophageal sphincter basal pressure, acid clearance time or acid suppression
- antibiotics within 60 days
- Nursing mothers will be excluded
- allergies to citrus
- asthma
- chronic lung disease
- heart attack or stroke within the last three months
- hypersensitivity to methacholine products
- know aortic aneurysm
- uncontrolled hypertension (defined as systolic pressure greater than 200 or diastolic greater than 100)
- reduced pulmonary function test (forced expiratory volume in one second (FEV1) or the FEV1 to forced vital capacity (FVC) ratio (FEV1/FVC) of less that 70% of predicted value)
- None of the controls will have any GERD symptoms or ever used antireflux treatment.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Healthy Volunteers
Subjects in this arm were healthy volunteers.
Subjects underwent both Cough Reflex Sensitivity and the Methacholine Challenge procedures.
|
Subjects inhaled increasing concentrations of citric acid, which induces coughing in a dose-dependent, reproducible matter.
Following each inhalation, the number of coughs in the subsequent 15 seconds was counted and recorded.
The challenge was terminated once the citric acid induced 5 or more coughs and the logarithmic (base 10) concentration provoking 5 coughs was recorded.
A baseline spirometry was used to assess how well the participant's lungs work by measuring how much air was inhale, how much was exhale and how quickly the participant exhaled.
If this was normal, the subject inhaled slowly and deeply the methacholine test solution from a nebulizer and was told to hold their breath for 5 seconds.
This was repeated until 5 inhalations were performed in no more than two minutes.
|
|
Non-erosive reflux disease with reflux
Subjects enrolled in this arm had non-erosive reflux disease with reflux (heartburn) for at least 6 of the preceding 12 months.
Subjects underwent both Cough Reflex Sensitivity and the Methacholine Challenge procedures.
|
Subjects inhaled increasing concentrations of citric acid, which induces coughing in a dose-dependent, reproducible matter.
Following each inhalation, the number of coughs in the subsequent 15 seconds was counted and recorded.
The challenge was terminated once the citric acid induced 5 or more coughs and the logarithmic (base 10) concentration provoking 5 coughs was recorded.
A baseline spirometry was used to assess how well the participant's lungs work by measuring how much air was inhale, how much was exhale and how quickly the participant exhaled.
If this was normal, the subject inhaled slowly and deeply the methacholine test solution from a nebulizer and was told to hold their breath for 5 seconds.
This was repeated until 5 inhalations were performed in no more than two minutes.
|
|
Non-erosive reflux disease without reflux
Subjects enrolled in this arm had non-erosive reflux disease with normal levels of reflux (heartburn).
Subjects underwent both Cough Reflex Sensitivity and the Methacholine Challenge procedures.
|
Subjects inhaled increasing concentrations of citric acid, which induces coughing in a dose-dependent, reproducible matter.
Following each inhalation, the number of coughs in the subsequent 15 seconds was counted and recorded.
The challenge was terminated once the citric acid induced 5 or more coughs and the logarithmic (base 10) concentration provoking 5 coughs was recorded.
A baseline spirometry was used to assess how well the participant's lungs work by measuring how much air was inhale, how much was exhale and how quickly the participant exhaled.
If this was normal, the subject inhaled slowly and deeply the methacholine test solution from a nebulizer and was told to hold their breath for 5 seconds.
This was repeated until 5 inhalations were performed in no more than two minutes.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Change in cough reflex sensitivity (CRS)
Periodo de tiempo: baseline, approximately 4 weeks
|
baseline, approximately 4 weeks
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Kenneth R. DeVault, MD, Mayo Clinic
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
1 de diciembre de 2012
Finalización primaria (Actual)
1 de febrero de 2016
Finalización del estudio (Actual)
1 de febrero de 2016
Fechas de registro del estudio
Enviado por primera vez
24 de enero de 2013
Primero enviado que cumplió con los criterios de control de calidad
24 de enero de 2013
Publicado por primera vez (Estimar)
29 de enero de 2013
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
17 de febrero de 2017
Última actualización enviada que cumplió con los criterios de control de calidad
16 de febrero de 2017
Última verificación
1 de febrero de 2017
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Enfermedades de las vías respiratorias
- Trastornos de la respiración
- Enfermedades Gastrointestinales
- Enfermedades bronquiales
- Signos y Síntomas Respiratorios
- Trastornos de la motilidad esofágica
- Trastornos de la deglución
- Enfermedades esofágicas
- Reflujo gastroesofágico
- Tos
- Hiperreactividad bronquial
- Efectos fisiológicos de las drogas
- Agentes neurotransmisores
- Mecanismos moleculares de acción farmacológica
- Agentes Autonómicos
- Agentes del sistema nervioso periférico
- Agentes colinérgicos
- Agonistas colinérgicos
- Agentes del sistema respiratorio
- Mióticos
- Parasimpaticomiméticos
- Agentes broncoconstrictores
- Agonistas muscarínicos
- Cloruro de metacolina
Otros números de identificación del estudio
- 11-006873
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
NO
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .